Clinical Trial Update: A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating Tarceva (erlotinib) in patients with advanced non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Genentech, Inc. | Conditions: Lung Cancer, Non-small-cell Lung Carcinoma | Phase 3 | Status: COMPLETED